case_images: PMC7253587_01
case_images: Total urine glycosaminoglycans at baseline and after starting enzyme replacement therapy. Normal range 0-16 mg/mmol creatinine.
case_images: fimmu-11-01000-g0001.jpg
case_images: PMC7253587_01_fimmu-11-01000-g0001.jpg
case_images: F1
case_images: Urine total glycosaminoglycans, dermatan sulfate, and heparan sulfate have significantly improved while receiving ERT as illustrated in (Figures 1-3), respectively.
case_images: Urine dermatan sulfate at baseline and after initiation of enzyme replacement therapy. Normal range 0-7.93 g/mmol creatinine.
case_images: fimmu-11-01000-g0002.jpg
case_images: PMC7253587_01_fimmu-11-01000-g0002.jpg
case_images: F2
case_images: Urine total glycosaminoglycans, dermatan sulfate, and heparan sulfate have significantly improved while receiving ERT as illustrated in (Figures 1-3), respectively.
case_images: Urine heparan sulfate at baseline and after initiation of enzyme replacement therapy. Normal range 0-5.71 g/mmol creatinine.
case_images: fimmu-11-01000-g0003.jpg
case_images: PMC7253587_01_fimmu-11-01000-g0003.jpg
case_images: F3
case_images: Urine total glycosaminoglycans, dermatan sulfate, and heparan sulfate have significantly improved while receiving ERT as illustrated in (Figures 1-3), respectively.